200 related articles for article (PubMed ID: 3259973)
1. Emergence of a B lymphocyte population with ADCC effector function in mammary tumor bearing mice.
Padmanabhan RR; Paul RD; Watson GA; Lopez DM
J Leukoc Biol; 1988 Jun; 43(6):509-19. PubMed ID: 3259973
[TBL] [Abstract][Full Text] [Related]
2. Nuclear disintegration of target cells by killer B lymphocytes from tumor-bearing mice.
Lopez DM; Blomberg BB; Padmanabhan RR; Bourguignon LY
FASEB J; 1989 Jan; 3(1):37-43. PubMed ID: 2783411
[TBL] [Abstract][Full Text] [Related]
3. NK cells from mammary tumor bearing mice do not exert natural killer activity but function as antibody dependent cellular cytotoxicity effectors.
Rivera LM; Lopez DM
Anticancer Res; 1993; 13(1):177-84. PubMed ID: 8476211
[TBL] [Abstract][Full Text] [Related]
4. Natural cytotoxicity against mouse hepatitis virus-infected cells. II. A cytotoxic effector cell with a B lymphocyte phenotype.
Welsh RM; Haspel MV; Parker DC; Holmes KV
J Immunol; 1986 Feb; 136(4):1454-60. PubMed ID: 3003199
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the effector cells mediating an "innocent bystander" cytotoxicity reaction induced by a syngeneic mammary adenocarcinoma in mice.
Paul RD; Padmanabhan R; Lopez DM
Cancer Res; 1984 Oct; 44(10):4480-6. PubMed ID: 6467207
[TBL] [Abstract][Full Text] [Related]
6. Induction of "innocent bystander" cytotoxicity in nonimmune mice by adoptive transfer of L3T4+ Lyt-1+2- mammary tumor immune T-cells.
Paul RD; Lopez DM
Cancer Res; 1987 Feb; 47(4):1105-10. PubMed ID: 2879623
[TBL] [Abstract][Full Text] [Related]
7. Mouse mammary tumor virus (MMTV) antigen(s) are present on B lymphocytes of BALB/c mice.
Charyulu V; Sigel MM; Durden DL; Lopez DM
Int J Cancer; 1979 Dec; 24(6):813-8. PubMed ID: 94593
[TBL] [Abstract][Full Text] [Related]
8. Dependence of initiation of an innocent bystander cytotoxicity reaction on the association of viral antigens and tumor cell membranes in mice.
Lopez DM; Lopez PF; Parks WP; Paul RD
J Natl Cancer Inst; 1986 May; 76(5):923-31. PubMed ID: 2871214
[TBL] [Abstract][Full Text] [Related]
9. Influence of mammary tumor progression on phenotype and function of spleen and in situ lymphocytes in mice.
Buessow SC; Paul RD; Lopez DM
J Natl Cancer Inst; 1984 Jul; 73(1):249-55. PubMed ID: 6610791
[TBL] [Abstract][Full Text] [Related]
10. Human antibody-dependent cellular cytotoxicity. Isolation and identification of a subpopulation of peripheral blood lymphocytes which kill antibody-coated autologous target cells.
Brier AM; Chess L; Schlossman SF
J Clin Invest; 1975 Dec; 56(6):1580-6. PubMed ID: 53242
[TBL] [Abstract][Full Text] [Related]
11. The role of tumor-derived cytokines on the immune system of mice bearing a mammary adenocarcinoma. I. Induction of regulatory macrophages in normal mice by the in vivo administration of rGM-CSF.
Fu YX; Watson GA; Kasahara M; Lopez DM
J Immunol; 1991 Jan; 146(2):783-9. PubMed ID: 1824777
[TBL] [Abstract][Full Text] [Related]
12. Emergence of a subpopulation of lymphocytes bearing theta antigen and complement receptor during tumor growth.
Epstein RS; Lopez DM; Ortiz-Muniz G; Sigel MM
Int J Cancer; 1976 Oct; 18(4):458-61. PubMed ID: 789259
[TBL] [Abstract][Full Text] [Related]
13. Suppressor cells in mice with murine mammary tumor virus-induced mammary tumors. I. Inhibition of mitogen-induced lymphocyte stimulation.
Rudczynski AB; Mortensen RF
J Natl Cancer Inst; 1978 Jan; 60(1):205-11. PubMed ID: 203703
[TBL] [Abstract][Full Text] [Related]
14. B cell subsets in spleens of BALB/c mice: identification and isolation of MMTV-expressing and MMTV-responding subpopulations.
Lopez DM; Charyulu V; Paul RD
J Immunol; 1985 Jan; 134(1):603-7. PubMed ID: 2981095
[TBL] [Abstract][Full Text] [Related]
15. Subset of spleen lymphocytes from BALB/cCrgl mice stimulated by mouse mammary tumor virus.
Lopez DM; Charyulu V; Sigel MM
Cancer Res; 1981 Mar; 41(3):813-8. PubMed ID: 6257384
[TBL] [Abstract][Full Text] [Related]
16. Antibody-dependent cellular cytotoxicity mediated by murine lymphocytes activated in recombinant interleukin 2.
Shiloni E; Eisenthal A; Sachs D; Rosenberg SA
J Immunol; 1987 Mar; 138(6):1992-8. PubMed ID: 3493293
[TBL] [Abstract][Full Text] [Related]
17. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
18. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
Mokyr MB; Ye QW
Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
[TBL] [Abstract][Full Text] [Related]
19. Soluble and membrane-bound TNF-alpha are involved in the cytotoxic activity of B cells from tumor-bearing mice against tumor targets.
Lopez-Cepero M; Garcia-Sanz JA; Herbert L; Riley R; Handel ME; Podack ER; Lopez DM
J Immunol; 1994 Apr; 152(7):3333-41. PubMed ID: 8144919
[TBL] [Abstract][Full Text] [Related]
20. Cyclophosphamide inhibits antibody-dependent cellular cytotoxicity (ADCC) suppression exerted by lymph node cells.
Palermo MS; Giordano M; Olabuenaga S; Isturiz MA
Cell Immunol; 1985 Jul; 93(2):438-46. PubMed ID: 2860977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
